DNMT3A and acute myeloid leukemia: However, it seems to be contradictory that hypomethylating agents, including azacytidine and decitabine, exhibit therapeutic effect on DNMT3A mutant AML patients [9, 10], which may be due to the changed flanking sequence preference of the aberrant DNMT3A enzyme that results in abnormal hypermethylation at some specific gene loci contributing to leukemogenesis [11, 12].